Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On August 13, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Centrum Broking, scheduled for August 21, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors. This engagement reflects Dr. Reddy’s commitment to maintaining transparency and communication with its stakeholders, potentially impacting investor relations and market perception.
The most recent analyst rating on (RDY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
Dr Reddy’s Laboratories exhibits strong financial fundamentals with consistent revenue and profit growth. However, bearish technical indicators and balanced earnings call sentiment due to challenges in the U.S. market and increased expenses weigh down the overall score. The valuation is reasonable, providing moderate income potential.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, focusing on generics, active pharmaceutical ingredients, and proprietary products. The company is listed on major stock exchanges including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 1,524,701
Technical Sentiment Signal: Hold
Current Market Cap: $11.62B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.